probdnf  (Alomone Labs)


Bioz Verified Symbol Alomone Labs is a verified supplier
Bioz Manufacturer Symbol Alomone Labs manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 92

    Structured Review

    Alomone Labs probdnf
    Dexmedetomidine could decrease the level of <t>proBDNF</t> and restore the ratio of proBDNF/mBDNF and alleviates activation of the proBDNF-P75NRT-RHOA pathway after sevoflurane. (a) Western blot band. (b) ProBDNF/mBDNF. (c–e) Bar graph of Western blot. (f) Immunofluorescence of proBDNF (scale bar = 50 μ m). ∗ Compare with the control group, P
    Probdnf, supplied by Alomone Labs, used in various techniques. Bioz Stars score: 92/100, based on 6 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/probdnf/product/Alomone Labs
    Average 92 stars, based on 6 article reviews
    Price from $9.99 to $1999.99
    probdnf - by Bioz Stars, 2022-12
    92/100 stars

    Images

    1) Product Images from "Dexmedetomidine Attenuates Neurotoxicity in Developing Rats Induced by Sevoflurane through Upregulating BDNF-TrkB-CREB and Downregulating ProBDNF-P75NRT-RhoA Signaling Pathway"

    Article Title: Dexmedetomidine Attenuates Neurotoxicity in Developing Rats Induced by Sevoflurane through Upregulating BDNF-TrkB-CREB and Downregulating ProBDNF-P75NRT-RhoA Signaling Pathway

    Journal: Mediators of Inflammation

    doi: 10.1155/2020/5458061

    Dexmedetomidine could decrease the level of proBDNF and restore the ratio of proBDNF/mBDNF and alleviates activation of the proBDNF-P75NRT-RHOA pathway after sevoflurane. (a) Western blot band. (b) ProBDNF/mBDNF. (c–e) Bar graph of Western blot. (f) Immunofluorescence of proBDNF (scale bar = 50 μ m). ∗ Compare with the control group, P
    Figure Legend Snippet: Dexmedetomidine could decrease the level of proBDNF and restore the ratio of proBDNF/mBDNF and alleviates activation of the proBDNF-P75NRT-RHOA pathway after sevoflurane. (a) Western blot band. (b) ProBDNF/mBDNF. (c–e) Bar graph of Western blot. (f) Immunofluorescence of proBDNF (scale bar = 50 μ m). ∗ Compare with the control group, P

    Techniques Used: Activation Assay, Western Blot, Immunofluorescence

    2) Product Images from "The decline in synaptic GluN2B and rise in inhibitory neurotransmission determine the end of a critical period"

    Article Title: The decline in synaptic GluN2B and rise in inhibitory neurotransmission determine the end of a critical period

    Journal: Scientific Reports

    doi: 10.1038/srep34196

    CS synapses in the ventral spinal cord were eliminated upon increasing synaptic 2B. ( A ) Reduction of CS synaptic activity in the ventral side after the critical period in 2a −/− mice. Spatial distribution of CS synapses determined using optical CS-EPSPs in WT, proBDNF-treated or 2a −/− mice at 11–13 or 14–16 DIV. Scale bar = 250 μm. ( B ) Ventrodorsal ratios of optical CS-EPSPs in the indicated culture pairs from 11–13 DIV (0.40 ± 0.03 in WT mice, n = 12, Ns = 12, Nm = 6; 0.42 ± 0.03 in 2a −/− mice, n = 6, Ns = 6, Nm = 6) or from 14–16 DIV (0.46 ± 0.02 in WT mice, n = 17, Ns = 17, Nm = 8; 0.39 ± 0.02 in proBDNF-treated mice, n = 4, Ns = 4, Nm = 4; 0.31 ± 0.03 in 2a −/− mice, n = 7, Ns = 7, Nm = 6).
    Figure Legend Snippet: CS synapses in the ventral spinal cord were eliminated upon increasing synaptic 2B. ( A ) Reduction of CS synaptic activity in the ventral side after the critical period in 2a −/− mice. Spatial distribution of CS synapses determined using optical CS-EPSPs in WT, proBDNF-treated or 2a −/− mice at 11–13 or 14–16 DIV. Scale bar = 250 μm. ( B ) Ventrodorsal ratios of optical CS-EPSPs in the indicated culture pairs from 11–13 DIV (0.40 ± 0.03 in WT mice, n = 12, Ns = 12, Nm = 6; 0.42 ± 0.03 in 2a −/− mice, n = 6, Ns = 6, Nm = 6) or from 14–16 DIV (0.46 ± 0.02 in WT mice, n = 17, Ns = 17, Nm = 8; 0.39 ± 0.02 in proBDNF-treated mice, n = 4, Ns = 4, Nm = 4; 0.31 ± 0.03 in 2a −/− mice, n = 7, Ns = 7, Nm = 6).

    Techniques Used: Activity Assay, Mouse Assay

    Decline in 2B-containing NMDAR across the end of the critical period. ( A ) Developmental alterations of the total NMDA component of CS-EPSCs in the spinal cord. Averaged CS-EPSC traces recorded after application of NBQX to WT ( upper ) or proBDNF-treated ( middle ) and 2a −/− ( lower ) mice before ( black ) or after ( red ) Ro25-6981 treatment on 12 DIV. Calibration: 50 pA, 100ms. ( B ) Averaged 2B-CS-EPSCs in WT (55.0 ± 14.6 pA, 6–8 DIV, n = 21, Ns = 16, Nm = 32; 18.0 ± 1.99 pA, 12–15 DIV, n = 18, Ns = 10, Nm = 20), proBDNF-treated (44.1 ± 6.45 pA, 12–15 DIV, n = 13, Ns = 8, Nm = 16) and 2a −/− mice (54.2 ± 10.8 pA, 6–8 DIV, n = 7, Ns = 7, Nm = 14; 74.4 ± 30.1 pA, 12–15 DIV, n = 7, Ns = 6, Nm = 12). ( C ) Developmental alterations of synaptic 2B in WT or 2a −/− mice. Immunoblot analysis of synaptic expression of 2B (2B in SPMs), PSD-95 (in SPMs) and MAGUKs (in SPMs) in WT and 2a −/− mice. Full-length blots are presented in Supplementary Fig. 7S . (D) Ratio of 2B to PSD-95 or MAGUKs in SPMs: To quantitate synaptic 2B, the intensity of 2B in SPMs was normalized to that of PSD-95 or MAGUK in SPMs in WT or 2a −/− spinal cords (Ratio of 2B to PSD-95: 1.00, 6 DIV in WT mice; 0.44, 13 DIV in WT mice; 0.62, 6 DIV in 2a −/− mice; 0.66, 13 DIV in 2a −/− mice. Ratio of 2B to MAGUKs: 1.00, 6 DIV in WT mice; 0.48, 13 DIV in WT mice; 0.75, 6 DIV in 2a −/− mice; 0.66, 13 DIV in 2a −/− mice. Each sample represents an SPM extract prepared from 20 co-cultures from 4 mice). Data are represented as the mean ± standard error of the mean. Asterisks indicate statistical significance (Student t test). * p
    Figure Legend Snippet: Decline in 2B-containing NMDAR across the end of the critical period. ( A ) Developmental alterations of the total NMDA component of CS-EPSCs in the spinal cord. Averaged CS-EPSC traces recorded after application of NBQX to WT ( upper ) or proBDNF-treated ( middle ) and 2a −/− ( lower ) mice before ( black ) or after ( red ) Ro25-6981 treatment on 12 DIV. Calibration: 50 pA, 100ms. ( B ) Averaged 2B-CS-EPSCs in WT (55.0 ± 14.6 pA, 6–8 DIV, n = 21, Ns = 16, Nm = 32; 18.0 ± 1.99 pA, 12–15 DIV, n = 18, Ns = 10, Nm = 20), proBDNF-treated (44.1 ± 6.45 pA, 12–15 DIV, n = 13, Ns = 8, Nm = 16) and 2a −/− mice (54.2 ± 10.8 pA, 6–8 DIV, n = 7, Ns = 7, Nm = 14; 74.4 ± 30.1 pA, 12–15 DIV, n = 7, Ns = 6, Nm = 12). ( C ) Developmental alterations of synaptic 2B in WT or 2a −/− mice. Immunoblot analysis of synaptic expression of 2B (2B in SPMs), PSD-95 (in SPMs) and MAGUKs (in SPMs) in WT and 2a −/− mice. Full-length blots are presented in Supplementary Fig. 7S . (D) Ratio of 2B to PSD-95 or MAGUKs in SPMs: To quantitate synaptic 2B, the intensity of 2B in SPMs was normalized to that of PSD-95 or MAGUK in SPMs in WT or 2a −/− spinal cords (Ratio of 2B to PSD-95: 1.00, 6 DIV in WT mice; 0.44, 13 DIV in WT mice; 0.62, 6 DIV in 2a −/− mice; 0.66, 13 DIV in 2a −/− mice. Ratio of 2B to MAGUKs: 1.00, 6 DIV in WT mice; 0.48, 13 DIV in WT mice; 0.75, 6 DIV in 2a −/− mice; 0.66, 13 DIV in 2a −/− mice. Each sample represents an SPM extract prepared from 20 co-cultures from 4 mice). Data are represented as the mean ± standard error of the mean. Asterisks indicate statistical significance (Student t test). * p

    Techniques Used: Mouse Assay, Expressing

    CS axons in the ventral spinal cord regressed upon increasing synaptic 2B. ( A ) Images of CS axons labeled with ChR2-EYFP in WT ( left ), proBDNF-treated and 2a −/− spinal explants ( right ). The first image was taken at 12 DIV and the second at 15 or 16 DIV. Enumeration of CS axons on the ventral side that crossed the 70% line ( red bold line ) from the dorsal to the ventral edge of spinal gray matter. Scale bar = 250 µm. ( B ) Ratios of CS axons on the ventral side at 15 or 16 DIV to that at 12 DIV (15 DIV/12 DIV: 1.13 ± 0.06 in WT mice, n = 9, Ns = 9, Nm = 4; 16 DIV/12 DIV: 0.60 ± 0.05 in proBDNF-treated mice, n = 11, Ns = 11, Nm = 6; 0.81 ± 0.05 in 2a −/− mice, n = 11, Ns = 11, Nm = 8) ( right ).
    Figure Legend Snippet: CS axons in the ventral spinal cord regressed upon increasing synaptic 2B. ( A ) Images of CS axons labeled with ChR2-EYFP in WT ( left ), proBDNF-treated and 2a −/− spinal explants ( right ). The first image was taken at 12 DIV and the second at 15 or 16 DIV. Enumeration of CS axons on the ventral side that crossed the 70% line ( red bold line ) from the dorsal to the ventral edge of spinal gray matter. Scale bar = 250 µm. ( B ) Ratios of CS axons on the ventral side at 15 or 16 DIV to that at 12 DIV (15 DIV/12 DIV: 1.13 ± 0.06 in WT mice, n = 9, Ns = 9, Nm = 4; 16 DIV/12 DIV: 0.60 ± 0.05 in proBDNF-treated mice, n = 11, Ns = 11, Nm = 6; 0.81 ± 0.05 in 2a −/− mice, n = 11, Ns = 11, Nm = 8) ( right ).

    Techniques Used: Labeling, Mouse Assay

    3) Product Images from "BDNF–TrkB signaling in the nucleus accumbens shell of mice has key role in methamphetamine withdrawal symptoms"

    Article Title: BDNF–TrkB signaling in the nucleus accumbens shell of mice has key role in methamphetamine withdrawal symptoms

    Journal: Translational Psychiatry

    doi: 10.1038/tp.2015.157

    Depression-like behavior and levels of proBDNF and BDNF in the brain regions after withdrawal from repeated METH exposure. ( a ) Schedule of treatment and behavioral tests. Saline (10 ml kg −1 per day for 5 days) or METH (3 mg kg −1 per day for 5 days) was injected into mice. Behavioral tests were performed at days 7, 11 and 18 (SPT), and days 8, 12 and 19 (LMT, TST, FST). ( b ) SPT: sucrose preference of METH-treated mice was significantly lower than that of control (saline-treated) mice. LMT: there were no differences between control and METH-treated mice. TST and FST: the immobility time of METH-treated mice was significantly higher than that of control mice. * P
    Figure Legend Snippet: Depression-like behavior and levels of proBDNF and BDNF in the brain regions after withdrawal from repeated METH exposure. ( a ) Schedule of treatment and behavioral tests. Saline (10 ml kg −1 per day for 5 days) or METH (3 mg kg −1 per day for 5 days) was injected into mice. Behavioral tests were performed at days 7, 11 and 18 (SPT), and days 8, 12 and 19 (LMT, TST, FST). ( b ) SPT: sucrose preference of METH-treated mice was significantly lower than that of control (saline-treated) mice. LMT: there were no differences between control and METH-treated mice. TST and FST: the immobility time of METH-treated mice was significantly higher than that of control mice. * P

    Techniques Used: Injection, Mouse Assay, Single-particle Tracking

    4) Product Images from "Human Immunodeficiency Virus-1 Alters Brain-derived Neurotrophic Factor Processing in neurons"

    Article Title: Human Immunodeficiency Virus-1 Alters Brain-derived Neurotrophic Factor Processing in neurons

    Journal: The Journal of neuroscience : the official journal of the Society for Neuroscience

    doi: 10.1523/JNEUROSCI.0865-12.2012

    Neuronal localization of proBDNF in human brains
    Figure Legend Snippet: Neuronal localization of proBDNF in human brains

    Techniques Used:

    pBDNF and proBDNF levels in HIV subjects
    Figure Legend Snippet: pBDNF and proBDNF levels in HIV subjects

    Techniques Used:

    gp120 alters the release of mBDNF/proBDNF in cortical neurons
    Figure Legend Snippet: gp120 alters the release of mBDNF/proBDNF in cortical neurons

    Techniques Used:

    gp120 increases proBDNF
    Figure Legend Snippet: gp120 increases proBDNF

    Techniques Used:

    Similar Products

  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 90
    Alomone Labs b 256 b biotin labled human probdnf
    B 256 B Biotin Labled Human Probdnf, supplied by Alomone Labs, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/b 256 b biotin labled human probdnf/product/Alomone Labs
    Average 90 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    b 256 b biotin labled human probdnf - by Bioz Stars, 2022-12
    90/100 stars
      Buy from Supplier

    92
    Alomone Labs probdnf
    Dexmedetomidine could decrease the level of <t>proBDNF</t> and restore the ratio of proBDNF/mBDNF and alleviates activation of the proBDNF-P75NRT-RHOA pathway after sevoflurane. (a) Western blot band. (b) ProBDNF/mBDNF. (c–e) Bar graph of Western blot. (f) Immunofluorescence of proBDNF (scale bar = 50 μ m). ∗ Compare with the control group, P
    Probdnf, supplied by Alomone Labs, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/probdnf/product/Alomone Labs
    Average 92 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    probdnf - by Bioz Stars, 2022-12
    92/100 stars
      Buy from Supplier

    Image Search Results


    Dexmedetomidine could decrease the level of proBDNF and restore the ratio of proBDNF/mBDNF and alleviates activation of the proBDNF-P75NRT-RHOA pathway after sevoflurane. (a) Western blot band. (b) ProBDNF/mBDNF. (c–e) Bar graph of Western blot. (f) Immunofluorescence of proBDNF (scale bar = 50 μ m). ∗ Compare with the control group, P

    Journal: Mediators of Inflammation

    Article Title: Dexmedetomidine Attenuates Neurotoxicity in Developing Rats Induced by Sevoflurane through Upregulating BDNF-TrkB-CREB and Downregulating ProBDNF-P75NRT-RhoA Signaling Pathway

    doi: 10.1155/2020/5458061

    Figure Lengend Snippet: Dexmedetomidine could decrease the level of proBDNF and restore the ratio of proBDNF/mBDNF and alleviates activation of the proBDNF-P75NRT-RHOA pathway after sevoflurane. (a) Western blot band. (b) ProBDNF/mBDNF. (c–e) Bar graph of Western blot. (f) Immunofluorescence of proBDNF (scale bar = 50 μ m). ∗ Compare with the control group, P

    Article Snippet: Immunofluorescence Assay The prepared brain slices were washed with 50 mM PBS for 3 times for 10 min each, and then, the slices were incubated in 3% H2 O2 for 30 min to block endogenous peroxidase activity, followed by immersion in blocking solution for 2 h and then incubated overnight with BDNF antibody (1 : 200, Abeam, Cambridge, UK) and proBDNF (1 : 50, Alomone Labs, Israel).

    Techniques: Activation Assay, Western Blot, Immunofluorescence